Sort   by:  
 Page size 
TranscriptomicsTranscriptome Analysis Predicts Clinical Outcome and Sensitivity to Anticancer Drugs of patients with a Pancreatic Adenocarcinoma
A major impediment to the effective treatment of patients with PDAC (Pancreatic Ductal Adenocarcinoma) is the molecular heterogeneity of the disease, which is reflected in an equally diverse pattern of clinical responses to therapy. We developed an efficient strategy in which PDAC samples from 17 co...
ORGANISM(S): Homo sapiens 
2015-04-09 | E-GEOD-55513 | biostudies-arrayexpress
ProteomicsThe tongue squamous carcinoma cell line Cal27 primarily employs integrin α6β4-containing type II hemidesmosomes for adhesion which contribute to anticancer drug sensitivity
Integrins are heterodimeric cell surface glycoproteins used by cells to bind to the extracellular matrix (ECM) and regulate tumor cell proliferation, migration and survival. A causative relationship between integrin expression and resistance to anticancer drugs has been demonstrated in different tum...
ORGANISM(S): Homo sapiens (Human) 
2022-02-16 | PXD028810 | Pride
Integrin crosstalk Hemidesmosome Laminin-332 Keratins 5/14 Adhesome Integrin αvβ3 Integrin α6β4 Anticancer drug sensitivity 
TranscriptomicsAnticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
Anticancer drug clustering in lung cancer based on gene expression profiles. We performed gene expression analysis in lung cancer cell lines. (used: Affymetrix GeneChip Human Genome U133 Array Set HG-U133A). We also examines the sensitivity of these cell lines to commonly used anti-cancer agents (do...
ORGANISM(S): Homo sapiens 
2006-02-10 | GSE4127 | GEO
TranscriptomicsTranscription profiling of human drug sensitive and resistant ALL cells obtained at diagnosis from 174 patients
Cellular drug resistance is associated with an unfavorable prognosis in pediatric acute lymphoblastic leukemia (ALL). To identify genes conferring resistance to antileukemic agents, we analyzed the expression of >12,700 genes in sensitive and resistant ALL cells obtained at diagnosis from 174 patien...
ORGANISM(S): Homo sapiens 
2008-06-15 | E-GEOD-635 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human prostatic cancer cell lines and sensitivity to an anticancer tumor agent
Transcriptional profiling was conducted on RNA from 16 prostatic cancer cell lines to identify genes whose expression level correlate with sensitivity of an anti-tumor agent Experiment Overall Design: Baseline gene expression profiling was performed using 16 prostatic cancer cell lines to identify e...
ORGANISM(S): Homo sapiens 
2008-06-16 | E-GEOD-9633 | biostudies-arrayexpress
GenomicsExpression dynamics of periodic transcripts during cancer cell cycle progression and their correlation with anticancer drug sensitivity
Expression dynamics of periodic transcripts during cancer cell cycle progression and their correlation with anticancer drug sensitivity
PRJNA894098 | ENA
GenomicsDrug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (gemcitabine)
Drug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (gemcitabine)
PRJNA478590 | ENA
GenomicsDrug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (geldanamycin)
Drug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (geldanamycin)
PRJNA478591 | ENA
GenomicsDrug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (dasatinib)
Drug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (dasatinib)
PRJNA478581 | ENA
GenomicsDrug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (cisplatin)
Drug-induced change in gene expression across NCI-60 cell lines after exposure to 15 anticancer agents for 2, 6 and 24h (cisplatin)
PRJNA478582 | ENA
Sort   by:  
 Page size